缺铁导致心力衰竭:细胞机制和治疗影响
Anastasios Tsarouchas1, Vassilios P Vassilikos1, Dimitrios Mouselimis1
1Third Department of Cardiology, Aristotle University of Thessaloniki, "Hippokration" General Hospital, 54642 Thessaloniki, Greece.
Journal of cardiovascular development and disease
|November 26, 2025
概括
缺铁 (ID) 严重影响心力衰竭 (HF) 患者,恶化症状和结果. 静脉注射铁疗法有效地减少了住院治疗,并改善了这些人的生活质量.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 内部医学 内部医学
背景情况:
- 缺铁 (ID) 常见于心力衰竭 (HF),影响高达75%的患者.
- 即使没有贫血,ID也会导致HF的症状和不良结果.
- 目前的诊断包括绝对和功能ID标准.
研究的目的:
- 审查当前对心力衰竭中缺铁的理解.
- 要突出新兴的治疗策略铁缺乏在HF.
- 识别诊断和治疗方面的知识差距.
主要方法:
- 关于主要临床试验的文献综述 (AFFIRM-AHF,IRONMAN,HEART-FID,FAIR-HF2).这些主要临床试验的研究结果包括:
- 在HF中综合目前的ID诊断标准.
- 分析欧洲心脏病学会的指导方针.
主要成果:
- 静脉注射铁,特别是铁性碳酸盐,可以减少HF住院.
- 治疗改善了ID的HF患者的生活质量和运动能力.
- 欧洲经济委员会 (ESC) 的指导方针建议IV铁性碳酸对具有ID的症状HFrEF患者进行治疗.
结论:
- 静脉注射铁疗法是对有症状的缺铁心力衰竭患者的推治疗方法.
- 需要进一步研究最佳诊断,铁和新的铁配方.
相关概念视频
Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
Heart Failure VI: Adjunct Therapies
239
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
239
Heart Failure II: Pathophysiology
693
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
693
Heart Failure V: Medical Management
204
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
204
Heart Failure I: Introduction
671
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
671
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K


